HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Effect of emodin on pancreatic fibrosis: experiment with rats].

AbstractOBJECTIVE:
To study the effect of emodin on pancreatic fibrosis and potential mechanism thereof.
METHODS:
Fifty SD rats were randomly divided into 5 equal groups: normal control group, model control group, low-dose emodin-treated group, mediate-dose emodin-treated group, and high-dose emodin-treated group. The rats of the latter 4 groups underwent infusion of trinitrobenzene sulfonic acid (TNBS) into the pancreatic duct so as to establish models of pancreatic fibrosis. The emodin-treated rats were fed with different doses of emodin (20, 40, and 80 mg/kg body weight), while the normal and model control groups received 0.9% sodium chloride solution instead. Twenty-eight days later the rats were killed, blood samples were collected, and their pancreases were taken out. The serum levels of hyaluronic acid (HA) and laminin (LN) were determined by radioimmunoassay. The histopathological alterations were studied by optical microscopy. The expression of collagen was examined by Van Gieson staining. Western blotting was used to detect the protein expression of transforming growth factor-beta(1) (TGF-beta(1)).
RESULTS:
(1) The serum level of HA of the low-dose, mediate-dose, and high-dose emodin-treated groups were 87 microg/L +/- 22 microg/L, 78 microg/L +/- 25 microg/L, and 62 microg/L +/- 19 microg/L respectively, all significantly lower than that of the model control group (113 microg/L +/- 27 microg/L, P < 0.05 or < 0.01). The serum levels of laminin in the low-dose, mediate-dose, and high-dose emodin-treated groups were 67 microg/L +/- 14 microg/L, 57 microg/L +/- 12 microg/L, and 44 microg/L +/- 10 microg/L respectively, all significantly lower than that of the model control group (86 microg/L +/- 17 microg/L, P < 0.05 or P < 0.01); (2) The degrees of fibrosis of the emodin-treated groups were obviously ameliorated in comparison with the model control group, the higher the dose of emodin the more improved the pathological changes, especially in the high-dose emodin-treated group (P < 0.05). (3) The percentages of collagen positive cells of the low-dose, mediate-dose, and high-dose emodin-treated groups were 39% +/- 7%, 38% +/- 4%, and 36% +/- 5% respectively, all lower than that of the model control group (42% +/- 6%), with a significant difference between the high-dose emodin-treated group and the model control group (P < 0.05). (4) The protein content of TGF-beta(1) of the low-dose, mediate-dose, and high-dose emodin-treated groups were 44.3% +/- 2.1%, 39.2% +/- 1.8%, and 28.8% +/- 1.6% respectively, all significantly lower than that of the model control group (60.7% +/- 1.7%, all P < 0.05), and the protein content of TGF-beta(1) of the high-dose emodin-treated group was significantly lower than those of the other 2 emodin-treated groups (both P < 0.05).
CONCLUSION:
Emoidn has an anti-fibrosis effect on pancreatic fibrosis, which maybe related to the content of TGF-beta(1) protein.
AuthorsCai-hua Wang, Zhi-qiang Gao, Bing Ye, Chuan-gao Xie, Ke-da Qian, Jian-ting Cai, Qin Du
JournalZhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 86 Issue 36 Pg. 2552-5 (Sep 26 2006) ISSN: 0376-2491 [Print] China
PMID17198564 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Laminin
  • Transforming Growth Factor beta
  • Trinitrobenzenesulfonic Acid
  • Hyaluronic Acid
  • Collagen
  • Emodin
Topics
  • Animals
  • Blotting, Western
  • Collagen (metabolism)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Emodin (therapeutic use)
  • Fibrosis
  • Hyaluronic Acid (blood)
  • Laminin (blood)
  • Male
  • Pancreas (drug effects, metabolism, pathology)
  • Pancreatic Diseases (blood, chemically induced, drug therapy)
  • Phytotherapy
  • Radioimmunoassay
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Transforming Growth Factor beta (biosynthesis)
  • Trinitrobenzenesulfonic Acid

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: